Your prediction
Sonnet Biotherapeutics Holdings Inc. Stock
Our community identified positive and negative aspects for Sonnet Biotherapeutics Holdings Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Sonnet Biotherapeutics Holdings Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Sonnet Biotherapeutics Holdings Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sonnet Biotherapeutics Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc. | - | - | - | - | - | - | - |
| Skylark Co Ltd | 0.000% | -6.630% | -6.630% | -5.056% | -5.056% | 43.220% | 32.031% |
| J D Wetherspoon plc | 2.190% | 6.061% | -6.667% | 6.061% | -15.152% | -17.501% | -56.030% |
| SSP Group plc | 2.000% | 2.564% | 1.010% | 36.054% | -8.257% | -28.058% | -45.578% |
Comments
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $30.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for SONN provided by MarketBeat